Leiyun Boone

FDA investigator

Appears on 8 documents from 2021 to 2025, most often at sites in Germany. Most often cites control of microbiological contamination (21 CFR 211.113).

8
Documents on file
5.1
Observations per 483
2021
First seen
2025
Most recent

What they cite most

From 36 observations

Activity by year

2021: 1, 2022: 1, 2023: 3, 2024: 2, 2025: 1

Where

Germany 2 · Denmark 1 · Iceland 1 · Massachusetts 1 · Rhode Island 1 · Switzerland 1

Is Leiyun Boone coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Alvotech HfJul 4, 2025 · Reykjavik, Iceland
483 FUJIFILM Diosynth Biotechnologies Denmark ApSNov 12, 2024 · Hillerod, Denmark
483 Vetter Pharma Fertigung GmbH & Co. KG (Ravensburg Mooswiesen)Mar 19, 2024 · Ravensburg, Germany
EIR Boehringer Ingelheim Biopharmaceuticals China Ltd.Jun 9, 2023
483 Rentschler Biopharma Inc.Mar 22, 2023 · Milford, Massachusetts
483 Rentschler Biopbanna SEMar 7, 2023 · Laupheim, Germany
483 Biogen International GmbHMar 29, 2022 · Luterbach, Switzerland

About this profile

What does Leiyun Boone inspect?

Leiyun Boone appears on 8 documents on file covering 8 sites, most often in Germany.

What do they cite most often?

21 CFR 211.113 (control of microbiological contamination), followed by 21 CFR 211.100 and 21 CFR 211.160.

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Leiyun Boone is dated Jul 4, 2025.